By Fineline Cube 
US-based Eli Lilly & Co. (NYSE: LLY) announced the launch of Mounjaro (tirzepatide multi-dose prefilled pen) in China, building on the earlier introduction of tirzepatide this year. This new delivery device aims to enhance supply and meet the needs of more patients in China.
Product Specifications
The tirzepatide multi-dose prefilled pen offers four fixed doses, with each administered weekly. It is available in four specifications:
- 2.4 mL: 10 mg (each pen contains 4 doses of 0.6 mL: 2.5 mg)
- 2.4 mL: 20 mg (each pen contains 4 doses of 0.6 mL: 5 mg)
- 2.4 mL: 30 mg (each pen contains 4 doses of 0.6 mL: 7.5 mg)
- 2.4 mL: 40 mg (each pen contains 4 doses of 0.6 mL: 10 mg)
Dosing Recommendations
The recommended starting dose is 2.5 mg administered subcutaneously once weekly. After four weeks, the dose should be increased to 5 mg. If further improvement in glycemic control or weight management is needed, the dose may be increased in 2.5 mg increments at intervals of at least four weeks.
Mechanism of Action
Tirzepatide is the first and only once-weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist approved globally for the treatment of type 2 diabetes and long-term weight management. The drug selectively binds to and activates the GIP and GLP-1 receptors, enhancing first- and second-phase insulin secretion in a glucose-dependent manner while reducing glucagon levels. It also improves insulin sensitivity and delays gastric emptying. Additionally, by modulating appetite through receptors in key brain regions, tirzepatide reduces food intake, body weight, and fat mass, while regulating lipid metabolism.-Fineline Info & Tech